ATE511835T1 - Biophosphonate zur behandlung von endometriose - Google Patents

Biophosphonate zur behandlung von endometriose

Info

Publication number
ATE511835T1
ATE511835T1 AT06711191T AT06711191T ATE511835T1 AT E511835 T1 ATE511835 T1 AT E511835T1 AT 06711191 T AT06711191 T AT 06711191T AT 06711191 T AT06711191 T AT 06711191T AT E511835 T1 ATE511835 T1 AT E511835T1
Authority
AT
Austria
Prior art keywords
endometriosis
biophosphonates
treatment
female subject
particles
Prior art date
Application number
AT06711191T
Other languages
English (en)
Inventor
Gershon Golomb
Haim Danenberg
Morey Schachter
Original Assignee
Hadasit Med Res Service
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Yissum Res Dev Co filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of ATE511835T1 publication Critical patent/ATE511835T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06711191T 2005-02-17 2006-02-16 Biophosphonate zur behandlung von endometriose ATE511835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65352605P 2005-02-17 2005-02-17
PCT/IL2006/000209 WO2006087722A1 (en) 2005-02-17 2006-02-16 Bisphosphonates for treating endometriosis

Publications (1)

Publication Number Publication Date
ATE511835T1 true ATE511835T1 (de) 2011-06-15

Family

ID=36178190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06711191T ATE511835T1 (de) 2005-02-17 2006-02-16 Biophosphonate zur behandlung von endometriose

Country Status (8)

Country Link
US (1) US8257742B2 (de)
EP (2) EP2316441A1 (de)
JP (2) JP4992091B2 (de)
AT (1) ATE511835T1 (de)
AU (1) AU2006215300C9 (de)
CA (1) CA2597699C (de)
ES (1) ES2366654T3 (de)
WO (1) WO2006087722A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3158867B1 (de) 2009-07-31 2018-12-12 Grünenthal GmbH Eine methode zur steigerung der wasserlösslichkeit einer bipshopshonsäure oder eines bisphosphonats
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US10517822B2 (en) 2013-11-06 2019-12-31 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
AU2015343202A1 (en) * 2014-11-03 2017-05-25 Bioincept, Llc PIF binding as a marker for immune dysregulation
PT3220908T (pt) 2014-11-18 2022-10-03 Univ South Florida Composições e métodos para o tratamento da endometriose
EP3439666A4 (de) 2016-05-20 2019-12-11 The University of Chicago Nanopartikel zur chemotherapie, gezielte therapie, photodynamische therapie, immuntherapie und alle kombinationen davon
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EP3638367A4 (de) 2017-08-02 2021-07-21 The University of Chicago Nanoskalige metallorganische schichten und metallorganische nanoplatten für die röntgenstrahlinduzierte photodynamische therapie, strahlentherapie, dynamische strahlentherapie, chemotherapie, immuntherapie und eine beliebige kombination davon

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
JPH0753593A (ja) * 1993-08-12 1995-02-28 Univ Pennsylvania 細胞浸潤の抑制
US5877284A (en) * 1993-08-12 1999-03-02 The Trustees Of The University Of Pennsylvania Isolated chemotactic factor from patients with endometriosis
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
WO2002096927A2 (en) * 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
WO1999040787A1 (en) * 1998-02-13 1999-08-19 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6346534B1 (en) * 1998-09-23 2002-02-12 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
NZ527157A (en) * 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
US7039638B2 (en) * 2001-04-27 2006-05-02 Hewlett-Packard Development Company, L.P. Distributed data clustering system and method
US20030018673A1 (en) * 2001-05-18 2003-01-23 Karl-Heinz Maier Physical units in a signal processing system
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
US20030064965A1 (en) * 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
US7090865B2 (en) * 2001-11-29 2006-08-15 National Jewish Medical And Research Center Composition and method for treating autoimmune hemolytic anemia
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
EP1494649B1 (de) * 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanopartikuläre megestrol- formulierungen
US20050255152A1 (en) * 2002-04-18 2005-11-17 President And Fellows Of Harvard College System for enhanced targeted delivery
DE60330860D1 (de) * 2002-06-12 2010-02-25 Boston Scient Ltd The Corporat Medizinische schlinge
WO2004073610A2 (en) * 2003-02-13 2004-09-02 Merck & Co., Inc. Estrogen receptor modulators
EP1603535A4 (de) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase-hemmer-diagnose und therapie
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050008633A1 (en) * 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
WO2005002545A1 (en) 2003-06-27 2005-01-13 Biorest Ltd. Method of treating acute coronary syndromes

Also Published As

Publication number Publication date
JP2011252017A (ja) 2011-12-15
AU2006215300B9 (en) 2010-01-28
WO2006087722A1 (en) 2006-08-24
CA2597699C (en) 2012-07-31
AU2006215300C1 (en) 2009-12-17
JP2008530200A (ja) 2008-08-07
AU2006215300A1 (en) 2006-08-24
JP4992091B2 (ja) 2012-08-08
CA2597699A1 (en) 2006-08-24
US20090238876A1 (en) 2009-09-24
EP1865935A1 (de) 2007-12-19
EP2316441A1 (de) 2011-05-04
EP1865935B1 (de) 2011-06-08
AU2006215300B2 (en) 2009-08-20
ES2366654T3 (es) 2011-10-24
AU2006215300C9 (en) 2010-05-06
US8257742B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
IN2015DN01786A (de)
MY161991A (en) Proteasome inhibitors
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EP1572075A4 (de) Verfahren zur behandlung von krankheiten in verbindung mit abnormaler kinasewirkung
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
PH12015501193A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
ATE511835T1 (de) Biophosphonate zur behandlung von endometriose
TW200806299A (en) Treatment of pain
EA200802054A1 (ru) Ингибиторы фермента
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
DE602004019897D1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
TW200716145A (en) Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
EA200800537A1 (ru) Маррубиин и композиция для уменьшения храпа, упаковка и методика
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties